Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Phase II Trial to Describe the Safety and Efficacy of Treosulfan-based Conditioning Therapy Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Paediatric Patients With Haematological Malignancies

NCT02333058 is registered in ClinicalTrials.gov with medac GmbH as lead sponsor.

NCT NCT02333058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02333058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Phase II Trial to Describe the Safety and Efficacy of Treosulfan-based Conditioning Therapy Prior to Allogeneic Haematopoietic Stem Cell Transplantation in Paediatric Patients With Haematological Malignancies
Lead sponsor
medac GmbH
Phase
Phase 2
Overall status
Completed
Start date
November 21, 2014
Completion date
September 30, 2019
Enrollment
70 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukaemias (all), acute myeloid leukaemias (aml), juvenile myelomonocytic leukaemias (jmml), myelodysplastic syndromes (mds)